Skip to main content

  • FDA Approval and First Implant of Orsiro Mission Drug-Eluting Stent System in the U.S.

    Full Commercial Launch Underway for the Latest Generation of BIOTRONIK’s Ultrathin Strut DES, Providing Advanced Deliverability for the outstanding Orsiro DES 

    BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro® Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The company also announced the first US implant and full commercial availability in the U.S.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details